RxDoctor Payments Data

Anthony Grillo, MD

Cornea and External Diseases Specialist · Lacey, WANPI 1104117589

Payments from drug & device makers

$4,901in general payments, 2019–2025

Across 118 payments — averaging $41.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Biotissue Holdings Inc.$1K
  • Sun Pharmaceutical Industries Inc.$357
  • Regeneron Healthcare Solutions, Inc.$198
  • Johnson & Johnson Surgical Vision, Inc.$184
  • AbbVie$84
  • plus $336 from 10 others

What the payments were for

  • Travel & lodging$73815%
  • Food & beverage$4,13884%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$506,448
Medicare patients
970
Services billed
2,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine81$87,595
XiidraLifitegrast34$36,423
Prednisolone Acetate465$21,534
Cyclosporine27$17,367
LumiganBimatoprost12$8,515
Fluorometholone83$7,466
Loteprednol Etabonate14$2,815
Difluprednate24$2,103
Doxycycline Hyclate41$1,979
ValacyclovirValacyclovir Hcl56$1,935
Ofloxacin141$1,759
Brimonidine Tartrate31$1,558
Doxycycline Monohydrate47$1,449
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha122$1,343
Timolol Maleate79$984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$84$96,11093 claims
Bausch & Lomb Americas Inc.Xiidra$31$36,42334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Lacey

Where these figures come from

Is this you, or does something look wrong? →